The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
This clinical study demonstrated that the 14-day regimen of ImmunoSEB and ProbioSEB CSC3 resolved post-Covid-19 fatigue symptoms and improved patients' functional status and quality of life
The trial will be conducted across eight sites in Maharashtra
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The company has to approach the DCGI for approval to commence the trials
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Subscribe To Our Newsletter & Stay Updated
